Original communication| Volume 79, ISSUE 2, P202-208, February 1976

Immunotherapy with neuraminidase-treated cells and bacillus Calmette-Guerin

      This paper is only available as a PDF. To read, Please Download here.


      Experiments were designed to determine the effectiveness of active immunotherapy, both specific (neuraminidase-treated cells) and nonspecific [bacillus Calmette-Guerin (BCG) organisms] in the L1210-BDF1 tumor-host system. Tumor burden was minimized with chemotherapy (l,3-bis-(2-chloroethyl)-1-nitrosourea) prior to immunotherapy. The effectiveness of immunotherapy was dependent on the amount of drug used to minimize tumor burden. An interval of 36 hours between chemotherapy and immunotherapy produced the maximum number of survivors. A single immunization with 104 neuraminidase-treated cells was superior to other single or multiple immunizations. BCG was most effective when mice were given 3.3 × 105 organisms. Beneficial effects of immunotherapy were observed only when immunizations were given by an intraperitoneal route. All mice cured of tumor developed tumor-specific immunity. The highest levels of immunity were observed in mice given both neuraminidase-treated cells and BCG organisms after chemotherapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bekesi J.G.
        • St. Arneault G.
        • Holland J.F.
        Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.
        Cancer Res. 1971; 31: 2130
        • Bekesi J.G.
        • St. Arneault G.
        • Walter L.
        • et al.
        Immunogenicity of leukemia L1210 cells after neuraminidase treatment.
        J. Natl. Cancer Inst. 1972; 49: 107
        • Catalona W.J.
        • Sample W.F.
        • Chretien P.B.
        Lymphocyte reactivity in cancer patients. Correlation with tumor histology and clinical stage.
        Cancer. 1973; 31: 65
        • Currie G.A.
        • Bagshawe K.D.
        Tumor-specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidate.
        Br. J. Cancer. 1969; 23: 141
        • Gatti R.A.
        Serum inhibitors of lymphocyte response.
        Lancet. 1971; 1: 1351
        • Hellström I.
        • Hellström K.E.
        • Sjögren H.O.
        • et al.
        Demonstration of cell-mediated immunity to human neoplasms of various histological types.
        Int. J. Cancer. 1971; 7: 1
        • Hellström I.
        • Sjögren H.O.
        • Warner G.
        • et al.
        Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms.
        Int. J. Cancer. 1971; 7: 226
        • Hersh E.M.
        • Gutterman J.U.
        • Mavligit G.
        Immunotherapy of cancer in man.
        Charles C Thomas, Publisher, Springfield, Ill1973
        • Holland J.F.
        E. pluribus unum: Presidential address.
        Cancer Res. 1971; 31: 1319
        • Killion J.J.
        • LeFever A.
        • Cantrell J.L.
        • et al.
        Immunotherapy of L1210 leukemia with isolated, antigenic subpopulations of L1210 cells.
        in: ed. 4. Proc. Am. Assoc. Cancer Res. 16. 1975: 22
        • Klein G.
        Tumor-specific transplantation antigens.
        Cancer Res. 1968; 28: 625
        • Kollmorgen G.M.
        • Killion J.J.
        • Sansing W.A.
        • et al.
        Combination chemotherapy and immunotherapy of transplantable murine leukemia. The cell cycle in malignancy and immunity.
        U. S. Atomic Energy Commission, Washington, DC1975
      1. LeFever, A., and Killion, J. J.: Unpublished data.

        • McKhann C.F.
        • Gunnarsson A.
        Approaches to immunotherapy.
        Cancer. 1974; 34: 1521
        • Old L.J.
        • Boyse E.A.
        Immunology of experimental tumors.
        Ann. Rev. Med. 1964; 15: 167
        • Prager M.D.
        • Derr I.
        • Swann A.
        • et al.
        Immunization with chemically modified lymphoma cells.
        Cancer Res. 1971; 31: 1488
        • Rios A.
        • Simmons R.
        Active specific immunotherapy of minimal residual tumor: Excision plus neuraminidase-treated tumor cells.
        Int. J. Can. 1974; 13: 71
        • Sanford B.H.
        • Codington J.F.
        Further studies on the effect of neuraminidase on tumor cell transplantability.
        Tissue Antigens. 1971; 1: 153
      2. Sansing, W. A., and Kollmorgen, G. M.: Unpublished data.

        • Santos G.W.
        Immunosuppressive drugs I.
        in: ed. 4. Fed. Proc. 26. 1967: 907
        • Simmons R.L.
        • Rios A.J.
        Immunotherapy of cancer: Immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG.
        Science. 1971; 174: 591
        • Simmons R.L.
        • Rios A.
        Immunospecific regression of methylcholanthrene fibrosarcoma using neuram-inidase. IV. Chemotherapeutic agents reverse the effects of tumor immunotherapy.
        Bull. Bell Museum. 1972; 2: 28
        • Simmons R.L.
        • Rios A.
        Neuraminidase and concanavalin A in the experimental immunotherapy of cancer.
        Johns Hopkins J. 1974; 3: 75
        • Simmons R.L.
        • Rios A.
        Cell surface modification in the treatment of experimental cancer: Neuraminidase or concanavalin A.
        Cancer. 1974; 34: 1541
        • Simmons R.L.
        • Rios A.
        • Lundgren G.
        • et al.
        Immuno-specific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase.
        Surgery. 1971; 70: 38
        • Sjögren H.O.
        • Hellström I.
        • Bansal S.C.
        • et al.
        Elution of “blocking factors” from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes.
        Int. J. Cancer. 1972; 9: 274
        • Weiss L.
        Guest editorial: Neuraminidase, sialic acids, and cell interactions.
        J. Nat. Cancer Inst. 1973; 50: 3